Capmatinib, a selective MET TKI, has been approved by the FDA for use in patients with MET exon 14-mutated NSCLC based on favorable response rates demonstrated in the GEOMETRY mono-1 trial [11]. This evidence concerns the gene MET and non-small cell lung carcinoma.